Top 10 Railroad Stocks To Invest In 2015: OXiGENE Inc.(OXGN)
OXiGENE, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics to treat cancer and eye diseases in the United States. It primarily focuses on the development of vascular disrupting agents (VDAs) that disable and destroy abnormal blood vessels, which provide solid tumors a means of growth and survival, as well as associate with visual impairment in various ophthalmological diseases and conditions. The company?s products include ZYBRESTAT, which is in fosbretabulin in anaplastic cancer of the thyroid (FACT) trial?Phase 2/3 study for the treatment of anaplastic thyroid cancer; in fosbretabulin in advanced lung oncology (FALCON) trial?Phase 2 randomized and controlled study to treat non-small cell lung cancer; in Phase 2 Simon two-stage design study for the treatment of platinum-resistant ovarian cancer; and in Phase 2 randomized controlled study to treat platinum-relapsed but platinum sensitive ovarian cancer. Its products also comprise OXi4503 that is in Phase 1 dose-escalation study for the treatment of acute myelogenous leukemia and myelodysplastic syndromes; Phase 1b dose-ranging study to treat solid tumors with hepatic tumor burden; and Phase 1 dose-escalation study for the treatment of refractory solid tumors. In addition, the company?s products consist of ZYBRESTAT, which is in Phase 2 randomized, double-masked, placebo-controlled, single-dose study for proof-of-mechanism study in polypoidal choroidal vasculopathy. OXiGENE has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology, and OXi4503. The company was founded in 1988 and is headquartered in South San Francisco, California.Advisors' Opinion:
- [By Wallace Witkowski]
Shares of Oxigene Inc. (OXGN) more than doubled on very heavy volume after the microcap biotech sa! id a mid-stage study of its drug Zybrestat, when used with Roches Avastin, showed increased survival in ovarian cancer patients. Oxigene shares rallied 129% to $5.55 , and were one of the most heavily traded issues after hours with more than 4.2 million shares exchanging hands.
- [By Bryan Murphy]
For the second time in as many days, I find myself supporting the purchase of a suddenly-bullish stock by saying "this time is different". Yesterday I was talking about OXiGENE Inc. (NASDAQ:OXGN), but today I'm using the term to describe the bullishness that's unfurling with Neurometrix Inc. (NASDAQ:NURO). And just for the record, yes, I know the perils of the "this time is different" argument. I tend to cringe when I hear it, as (too much) experience has taught me that things are rarely different - patterns within the market play themselves out over and over again. In the case of NURO as well as OXGN though, I can put my finger on something specific that we've not yet seen.
- [By Bryan Murphy]
There's no denying that OXiGENE Inc. (NASDAQ:OXGN) has, if nothing else, an interesting pipeline. And for many investors, the prospect of one or two budding winners in development is more than enough reason to jump into a biotech stock. In the case of OXGN, however, there's a far more direct - and no less speculative - reason to become a shareholder. That reason? The stock's going higher.... seriously.
source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-10-railroad-stocks-to-invest-in-2015-3.html